10 FOREWORD 



longer gives a maximum response. This principle, combined 

 with the others, furnishes the basis for Proteal Therapy as at 

 present developed. 



The first of these discoveries was announced by the writer in 

 American Medicine of October and November, 1914 ; the second 

 had first detailed announcement in the writer's article in the New 

 York Medical Journal of October 2, 1915. The two discoveries 

 are interlinked and associated, but not necessarily interdependent. 

 Either one of them might be proved fallacious without necessarily 

 affecting the status of the other. But if both should be shown 

 to be true, it will appear that corollaries of practical importance 

 are associated with each that give mutual support to one another. 

 The third discovery was first publicly announced in a Monograph 

 issued December 1, 1916, under title of The Proteal Treatment 

 of Cancer and Allied Conditions. 



The above statement of principles may be considered as a 

 fundamental analysis or summary of the most novel contents of 

 this book. Let me now make an analysis of a slightly more 

 detailed character, outlining the observed facts that appear to 

 give support to one or the other of these principles, and the 

 various collateral theories associated therewith. 



The series of new facts, then, cited sequentially somewhat in 

 the order of their discovery, comprise the following : 



(1) Certain substances administered hypodermically have been 

 observed to have a definite influence on the clinical progress of 

 persons suffering from inoperable cancer of many types. These 

 substances include extracts of plant products and animal products 

 of many kinds ; but they have this point in common all of them 

 contain protein or the products of partial protein hydrolysis. 



(2) The observed modifications in cancer subjects through 

 administration of these substances include: Alleviation of pain, 

 modification of discharge, modification in the tumor itself, and 

 modification in the general health and mental attitude of the 

 patient. 



(3) The same protein substances, administered hypodermically, 

 have been observed to benefit markedly cases of (a) rheumatoid 

 arthritis, (1>) pulmonary tuberculosis, (c) pernicious anaemia, 

 (d) intestinal toxaemia, (e) leukaemia, (f) Graves' disease, (g) 

 psoriasis, (h) asthma, (i) arteriosclerosis, (j) neurasthenia, (k) 

 primary and secondary anaemias. 



(4) The clinical betterment of these cases has been observed to 

 be associated with blood modifications of a definite and pre- 

 dictable character, namely: increase of haemoglobin, increase in 

 number of red corpuscles, increase of large mononuclear leuco- 

 cytes, increase of eosinophiles, and modification of numbers of 

 polunuclears and small lymphocytes in the direction of the nor- 



